The Fold Variant BM4 Is Beneficial in a Therapeutic Bet v 1 Mouse Model
Background. Specific immunotherapy using recombinant allergens is clinically effective; still wild-type allergens can provoke treatment-induced side effects and often show poor immunogenicity in vivo. Thus, we tested the low IgE-binding, highly immunogenic fold variant BM4 in a Bet v 1 mouse model....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2013-01-01
|
| Series: | BioMed Research International |
| Online Access: | http://dx.doi.org/10.1155/2013/832404 |